Starting on 1 January 2025, the parallel import of medicines into Ukraine will come into force, allowing dealers that are authorised by manufacturers of medicinal products to import medicines in parallel with said manufacturers. The expected outcomes of this new regime are higher competition and lower prices for relevant medicines.

Oppenheim has advised Romania's MedLife Group affiliate Genesys Medical Clinic on the acquisition of Budapest-based VP-Med Health Centre from Attila Szabo and Olga Szegvari.

CMS has advised Werfen on its approximately USD 25 million acquisition of Omixon Biocomputing. Hogan Lovells advised Omixon.

Walless has advised Biomapas on a partnership with Carbyne Equity Partners. TGS Baltic advised Carbyne Equity Partners.

Earlier in 2024, DLA Piper published its Medical Devices Advertising: CEE Comparison Guide, which reviews advertising regulations for medical devices in Austria, Croatia, the Czech Republic, Hungary, Poland, Romania, Slovakia, and Slovenia. Life sciences team members who worked on the guide spoke with CEE Legal Matters about some of the regulatory differences across CEE and the practical implications for businesses.

Boyanov & Co has advised Bulgarian pharma company Sopharma on its acquisition of a pharmaceutical product portfolio consisting of both CHC and prescription products.